The USPTO published a patent application covering isotopically enriched variants of classic psychedelic compounds including 2-bromo-LSD, LSD, ALD-52, and 1P-LSD. The claimed inventions include novel chemical compositions and methods for their use in treating neurologic and brain disorders. The patent is classified under CPC codes including C07D 457/06 (lysergic acid derivatives), A61K 31/48, A61P 25/28, and A61P 25/32 covering nervous system and neurological disorder treatments.

Pharmaceutical companies and researchers developing psychedelic-based therapeutics should review this application to assess potential freedom-to-operate considerations and competitive landscape. This represents an emerging patent filing in the psychedelic medicine space targeting neurological applications. No immediate compliance actions are required as this is a pending patent application, not an issued patent or regulatory requirement.